PMA device
nMARQ Catheter Interference Cable
Biosense Webster, Inc. · Cardiac Ablation Percutaneous Catheter (LPB, Class III) · First FDA decision Nov 15, 2024, newest Nov 15, 2024Atrial fibrillation
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
PMA pathway
Device trials
9
Naming "nMARQ"
MAUDE reports
0
Brand "nMARQ", since 2015
PubMed studies
42
Mentioning "nMARQ"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing nMARQ Catheter Interference Cable
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- nMARQ Catheter Interference CablePMA supplement
P950005-S087 · Decided Nov 15, 2024 · 248 days after receipt · Normal 180 Day Track No User Fee
Device type: Cardiac ablation percutaneous catheter (LPB) · Cardiology
- nMARQ Catheter Interference CablePMA supplement
P040036-S097 · Decided Nov 15, 2024 · 248 days after receipt · Normal 180 Day Track No User Fee
Device type: Cardiac ablation percutaneous catheter (LPB) · Cardiology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Cardiac Catheterization Performed In Other Than A Hospital SettingNational analysisReview closedCAG-00166NUpdated Sep 16, 2026
- Cardiac Catheterization Performed in Other than a Hospital Setting - RETIREDNational determinationOn the books20.25Updated Dec 3, 2024
- Cardiac Catheterization and Coronary AngiographyLocal determinationIn effectL33959CGS Administrators, LLCUpdated Oct 30, 2026
- Cardiac Catheterization and Coronary AngiographyLocal determinationIn effectL33557Wellpoint FederalUpdated Jul 14, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "nMARQ", any status and sponsor, newest update first.
Biosense Webster, Inc.Public (JNJ)
NCT03459196 · 54 participants · Start Apr 2, 2018 · Primary completion Oct 8, 2018
Device: THERMOCOOL SMARTTOUCH SF-5D Catheter · For: Paroxysmal Atrial Fibrillation
Sites: Linz, Austria; Aalst, Belgium; Bruges, Belgium · 7 sites in all
- nMARQ™ Pulmonary Vein Isolation System for the Treatment of Paroxysmal Atrial FibrillationPivotal-lookingTerminated
Biosense Webster, Inc.Public (JNJ)
NCT01824394 · 481 participants · Start Apr 1, 2013 · Primary completion Nov 26, 2017
Device: nMARQ Navigation Catheters; NaviStar ThermoCool Catheters · For: Atrial Fibrillation
Biosense Webster, Inc.Public (JNJ)
NCT02991313 · 40 participants (planned) · Start Oct 1, 2016 · Primary completion Nov 30, 2018
Device: Endocardial Ablation Procedure · For: Persistent Atrial Fibrillation
6 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "nMARQ", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code LPB
14,593 reports: 5,424 malfunction, 8,535 injury, 628 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0139-2015 · Started Oct 19, 2014 · Posted by FDA Oct 27, 2014
Reason given: The recall was initiated because Biosense Webster is providing additional labeling for the safe and effective use of the ThermoCool SmartTouch Catheter.
Cause as FDA categorized it: Use error · Device type: Cardiac Ablation Percutaneous Catheter (LPB)
Published research
The most relevant PubMed records for "nMARQ"[tiab]. The summary above synthesizes these.
- Last call on nMARQࡊ safety.
Dekker LR · Europace · 2016Editorial, Comment
- nMARQ Ablation for Atrial Fibrillation: Results from a Multicenter Study.
Mahida S, Hooks DA, Nentwich K, et al. · J Cardiovasc Electrophysiol · 2015Multicenter Study, Research Support, Non-U.S. Gov't
- Single-catheter approach to pulmonary vein reisolation in selected patients : Data from a prospective registry.
Lauschke J, Schneider R, Wissmann J, et al. · Herz · 2016Controlled Clinical Trial
- Results of the first investigator-initiated randomized clinical trial of nMARQTM, PVACTM, and thoracoscopic ablation for paroxysmal atrial fibrillation.
Sugihara C, Furniss S, Hyde J, et al. · Europace · 2018Comparative Study, Randomized Controlled Trial
- One-year clinical outcome after ablation with a novel multipolar irrigated ablation catheter for treatment of atrial fibrillation: potential implications for clinical use.
Wakili R, Siebermair J, Fichtner S, et al. · Europace · 2016Comparative Study
- Ablation of atrial fibrillation and esophageal injury: Role of bipolar and unipolar energy using a novel multipolar irrigated ablation catheter.
Di Monaco A, Quadrini F, Katsouras G, et al. · Heart Rhythm · 2015
- Usefulness of intracardiac echocardiography during pulmonary vein isolation with the novel multipolar irrigated ablation catheter (nMARQࡊ).
Dello Russo A, Fassini G, Casella M, et al. · J Interv Card Electrophysiol · 2015
- Direct results of a prospective randomized study comparing ablation with the nMARQ catheter and the PVAC catheter used with and without a 3D system (MAPER 3D Study).
Koźluk E, Piitkowska A, Rodkiewicz D, et al. · Arch Med Sci · 2019
- Safety and Feasibility of Contrast Injection During Pulmonary Vein Isolation with the nMARQࡊ Multi-Electrode Catheter.
Farkash AL, Katz A, Cohen O, et al. · J Atr Fibrillation · 2015
- Radiofrequency Ablation of Atrial Fibrillation: Nonrandomized Comparison of Circular versus Point-by-Point "Smart" Ablation for Achieving Circumferential Pulmonary Vein Isolation and Curing Arrhythmic Symptoms.
Rosso R, Chorin E, Levi Y, et al. · J Cardiovasc Electrophysiol · 2016
- Silent cerebral infarcts following pulmonary vein isolation with different atrial fibrillation ablation techniques - incidence and risk factors.
Glowniak A, Tarkowski A, Janczarek M, et al. · Arch Med Sci · 2022
- Cerebral microembolization during atrial fibrillation ablation: comparison of different single-shot ablation techniques.
Kiss A, Nagy-Baló E, Sándorfi G, et al. · Int J Cardiol · 2014Comparative Study
Other devices of this type
Also filed under product code LPB.
- Therapy Ablation Catheter (4mm and 8mm)Irvine Biomedical, Inc. · PMA 2022
- Navistar ThermocoolBiosense Webster, Inc. · PMA 2014
- EZ Steer ThermoCool CatheterBiosense Webster, Inc. · PMA 2021
- Chilli II Cooled Ablation Catheter and CableBoston Scientific Corp · PMA 2020
- Livewire Tc Ablation Catheter, Safire Ablation CatheterSt Jude Medical · PMA 2016
- Chilli Cooled Ablation SystemBoston Scientific Corp · PMA 2011
- Blazer II Cardiac Ablation System and CableBoston Scientific Corp · PMA 2025
- Freezor Cardiac Cryoablation CatheterMedtronic Cryocath, LP · PMA 2022
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.